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Patients and Methods: Nineteen pts with a median age of 56
years (range 18–70) not eligible for ablative SCT received
Campath-1H 20 mg/m2, ﬂudarabine 25 mg/m2  5 days and
either cyclophosphamide 1 g/m2  2 days (n16 pts), melpha-
lan 140 mg/m2 (n1 pt) or busulfan 0.8 mg/m2  8 doses (n2
pts) followed by G-CSF stimulated peripheral blood (n13) or
unmanipulated bone marrow(n6). GVHD prophylaxis con-
sisted of CSA at least until T60 and mycophenolate mofetil
through T30. DLI was allowed for residual/progressive dis-
ease or mixed chimerism after T60 in absence of GVHD.
Seven pts had a previous autologous transplantation. Ten pts
had myeloid diseases (AML6, CML Ph negative1, CML
accelerated phase1, therapy related MDS1, myeloﬁbro-
sis1); 9 pts lymphoid (HD3, NHD5, PLL1); only 5 pts
were in CR at transplant. Six pts received bone marrow with a
median CD34 cells infused of 3.7  106/kg, and 13 pts pe-
ripheral blood with a median of 4.5  106/kg CD34 cells
infused. Results:19 achieved ANC 0.5  106/L within a
median of 12 days (range 8–16); 2 pts rejected the graft and 1
had autologous reconstitution; 10/19 achieved sustained platelet
engraftment at a median of 16 days (range 7–27). 2/17 pts with
sustained engraftment developed acute GVHD; 7/14 at risk pts
had CMV reactivation; TRM at T100 was 16% (disease pro-
gression in 2 and GVHD in 1). Nine pts received DLI (5 for
persistent mixed chimerism and 4 pts for persistent/progressive
disease). After DLI 5 pts had GVHD limited to skin. Of the pts
with myeloid malignancies 2 pts remain alive in CR at T28,
19 months; of the pts with lymphoid malignancies 2 pts with
HD are alive in CR at T34, 15 months and 2 pts with mantle
cell lymphoma are alive at T19, T13 months. Causes of
death include disease progression in 7 pts, CMV disease in 1 pt,
adenovirus/CMV disease in 1 pt, sepsis in 1 pt and GVHD in 3
pts. Conclusion: These results suggest that this approach is well
tolerated with a low early TRM even in pts with advanced
disease. Longer follow-up and better patient selection are
needed.
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UMBILICAL CORD BLOOD TRANSPLANTS (UCBT). EVALUATION OF
CHIMERISM AND SURVIVAL IN RELATION TO CD34 OR MONONUCLEAR
CELL (MNC) DOSE INFUSED. THE CHILDREN’S MEMORIAL HOSPITAL
(CMH) EXPERIENCE
Merchant, M.1; Olszewski, M.1; Duerst, R.1,2; Huang, W.1; Jacobsohn,
D.1,2; Kletzel, M.1,2 1. Children’s Memorial Hospital, Chicago, IL; 2.
Northwestern University Feinberg School of Medicine, Chicago, IL.
To evaluate chimerism and to determine if cell dose/kg has a
relationship with time to full chimerism in children undergoing
Hematopoietic UCBT unrelated (n85) related (n3) at CMH;
between 1995 and 2004, one hundred and one UCBT were per-
formed at CMH of those 88 meet the study criteria (survive 30
days post transplant) to be evaluable for engraftment and survival.
There were patients (pts) with malignant (n71) and non-malig-
nant (17) diseases with a mean age of 5.0 years (.6–16) and a mean
weight of 20.2 kg (5.6–61). The preparative regimen consisted of
fTBI (1200 cGy) day 8 to 5, VP-16 1000 mg/m2 day 4 and
cyclophosphamide 60 mg/kg/day days 3 to 1. GVHD prophy-
laxis consisted of CSA, short course MTX, ATG (days 1, 3, 5, 7).
Engraftment was deﬁned as the time to reach 95% donor chi-
merism, assessed by either ﬂuorescence in-situ hybridization or
variable number tandem repeats (VNTRs). Cell counts were mea-
sured by the Abbott Cell Dyne counter and the CD34 cells were
quantiﬁed by ﬂow cytometry on a FACS sorter. Pts were divided in
two groups according to cell doses received (
.7 or .7) for
CD34  106/kg and MNC  108/kg cells. Statistical analysis was
made by a non-parametric t test and column statistics (mean 	
SEM and all were at the 95% CI) on (Graph Pad). The overall
engraftment of the 88 patients was 72% (63/88). There was no
difference among the groups in volume infused, malignant or
non-malignant or the status of disease prior to transplant. Pts with
the lower CD34 and MNC cells infused were heavier and showed
a lower incidence of full chimerism and a trend to slower engraft-
ment. There was also a survival difference in favor of the higher
CD34 cell infused group.
Table 1. CD34  106/kg MNC  108/kg
Cell Doses <.7 >.7 p Value <.7 >.7 p Value
Age 6.8  0.8 4.0  3.6 0.002 6.6  0.5 2.2  .45 <0.0001
Weight 25.7  2.4 17.2  1.3 0.0015 24.8  1.6 12.5  1.1 <0.0001
Days to >95%
chimerism 37.3  4.6 30.8  2.9 0.2 34.8  3.3 29.6  3.7 0.3
% achieving full
chimerism 52.9 83.3 0.001 56.8 78.0 0.02
% Overall
survival 44.1 61.6 0.001 53.4 56.6 n/s
Number of
patients 34 54 58 30
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HEMATOPOIETIC CELL TRANSPLANTATION (HCT)-SPECIFIC-COMOR-
BIDITY INDEX: A NEW TOOL FOR RISK ASSESSMENT BEFORE ALLO-
GENEIC HCT
Sorror, M.L.1; Maris, M.B.1,2; Storb, R.F.1,2; Baron, F.1; Sandmaier,
B.M.1,2; Maloney, D.G.1,2; Barry, S.E.1,2 1. Fred Hutchinson Cancer
Research Center; 2. University of Washington, Seattle, WA.
We have reported on the use of Charlson comorbidity index
(CCI) to predict non-relapse mortality (NRM) and overall survival
(OS) for patients (pts) given nonablative or ablative HCT1. How-
ever, the sample size of pts with scores of1, captured by the CCI,
did not exceed 35%. Further, some of comorbidities were rarely
found among pts given HCT. Therefore, we sought to develop an
HCT-speciﬁc-comorbidity index aimed at a) better deﬁning pre-
viously identiﬁed comorbidities, i.e. adding pulmonary functions
tests to pulmonary, liver function tests to hepatic, and ejection
fraction 50% to cardiac comorbidities and b) investigating addi-
tional HCT-related comorbidities. To this end, we retrospectively
reviewed comorbidities of 1055 pts given HCT at our center
between 1997–2003 after nonablative (n294) or ablative (n761)
conditioning. Pts were randomly divided into training (n708) and
validation sets (n347). In the training set, the unadjusted hazard
ratios (HR) for 2-year NRM were calculated for each comorbidity
and then adjusted for other comorbidities, disease risk, and condi-
tioning type. The adjusted HRs were employed as weights for
individual comorbidities. Differences encountered compared to
the original CCI were: a) two new comorbidities were added
(obesity  score 1 and peritransplantation infection  score 2), b)
age 50 years acquired a score of 2, and c) hypertension and
asthma each acquired a score of 1 instead of 0, moderate pulmo-
nary, peptic ulcer, and rheumatologic each acquired a score of 2
instead of 1, valvular heart disease a score of 2 instead of 0, and
severe pulmonary comorbidity a score of 3 instead of 1. In the
training set, HR for NRM for scores 0, 1, 2, 3, 4, 5 were 1, 1.2,
3.5, 6.1, 7.1, and 10.8, respectively. The modiﬁed index was then
validated using the validation set. This index had the advantage of
1) capturing more pts with high scores and 2) distinguishing pts
with low scores who had lower NRM and better OS when com-
pared to the original CCI (Table). Applying the scores to nonab-
lative and ablative pts, respectively, NRM of 5 vs 10% (p0.4) and
OS of 85% vs 75% (p0.1) were seen for scores of 0–1, 17 vs 27%
(p0.04) and 61 vs 59% (p0.2) for scores of 2–3, and 33 vs 54%
(p0.03) and 43 vs 30% (p0.006) for scores of 4. This HCT-
speciﬁc comorbidity index provides a simple, readily applicable and
valid method of estimating NRM and OS among pts given nona-
blative or ablative allogeneic HCT. (1. Sorror et al. Blood. 2004;
104:961.)
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Table. Percentages of pts and Two-Year Rates of NRM and OS in
the Validation Set (n  346) as Scored by the New HCT-Speciﬁc
Comorbidity Index Compared to the Original CCI
HCT-CI pts, %
Two-Year Rate
Original CCI pts, %
Two-Year Rate
NRM, % OS, % NRM, % OS, %
0–1 37 13 72 0 58 17 64
2–3 36 22 58 1 27 33 51
>4 27 40 35 >2 15 31 41
NRM indicates non-relapse mortality; OS, overall survival; CCI,
Charlson comorbidity index; and HCT-CI, hematopoietic cell
transplantation-speciﬁc comorbidity index.
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EFFECTS OF NATURAL KILLER (NK) CELLS ON ALLOGENEIC BONE
MARROW TRANSPLANTATION (BMT) IN FETAL AND NEWBORN MICE
Bhattacharyya, S.; Cowan, M.J. UCSF Children’s Hospital, San Fran-
cisco, CA.
NK cells are capable of receptor-mediated lysis of target cells that
lack self class I MHC molecules. Thus, it is possible that they can be
used effectively in an MHC I mismatched allogeneic BMT to create
myeloablation without developing GVHD. We wanted to deﬁne the
role of the NK cell as a myeloablative agent. C57Bl/6 (B6) adult NK
cells were injected i.p. into 2 day old Balb/c newborns. At various
times post transplant, bone marrow was harvested and in-vitro colony
forming assays were done. We found that allogeneic NK cells de-
stroyed both erythroid and myeloid progenitor cells by 5 days post
injection with some recovery by 19 days. We then injected NK cells
with/without bone marrow from C57Bl/6 (B6) mice into 14 day old
Balb/c fetuses and newborn animals. We found that none of the fetal
recipients survived the in utero transplants even when the number of
NK cells was reduced to 10,000 cells. Histologic studies suggested
severe liver toxicity associated with the fetal injections. In contrast,
7/10 newborn recipients of allogeneic lin BM and NK cells had
multi-lineage engraftment 8 weeks post transplant (Table). The en-
graftment was inhibited by co-administration of anti NK1.1 mAb or
anti-TGF beta antibody suggesting that NK cells play a role in the
engraftment and mediate their effect at least partially through the
secretion of TGF-beta. We used an Artemis deﬁcient TBNK
mouse to study the repopulation of the marrow following transplant
with NK cells. We found signiﬁcant repopulation of T cells (36 	
17% vs 7	 2% control) in blood and thymus with evidence of B cell
reconstitution in bone marrow. NK cells can be used effectively as a
means of enhancing donor cell engraftment and in some circum-
stances inducing multilineage engraftment. This work was supported
by a grant from the NIH NIAID RO1 HL58842 (Table 1).
Engraftment (Percent) in Newborn Balb/c Recipients of B6 NK Cells
and Lin Bone Marrow at 8 Weeks
Groups
Animals
Engrafted
CD3
Cells Granulocytes B Cells Monocytes NK Cells
BM Alone 0/4 0.39  0.11 0.1  0.02 0.1  0.04 0.1  0.02
None
detected
NK  BM 7/10 16.5  6.3 0.5  0.7 2.6  1.0 1.4  1.8 2.1  0.6
NK Alone 3/10
None
detected
None
detected
None
detected
None
detected 5.11  1.4
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LONG TERM INFECTIOUS COMPLICATIONS FOLLOWING REDUCED IN-
TENSITY CONDITIONING (RIC) ALLOGENEIC HLA-IDENTICAL SIBLING
TRANSPLANTATION (ALLO-SCT)
Etienne, A.1; Mohty, M.1; Faucher, C.1; Ferrando, M.1; Benramdane,
R.1; Zandotti, C.2; Collet, L.1; Vey, N.1; Stoppa, A.M.1; Coso, D.1;
Viens, P.1; Gastaut, J.A.1; Blaise, D.1 1. Institut Paoli-Calmettes,
Marseille, France; 2. CHU Timone, Marseille, France.
We analyzed infections occurring beyond 6 months after allo-
SCT, in 81 consecutive pts who received a RIC prior to allo-SCT
from HLA-identical siblings: median age was 49 (18–63) years. 33
(41%), 34 (42%) and 14 (17%) pts had respectively a myeloid,
lymphoid or non-hematological malignancy. 62 pts (77%) had an
advanced disease with high risk clinical features precluding the use
of standard myeloablative allo-SCT. 21 pts (26%) BMT and 60
(74%) PBSCT. RIC consisted of ﬂudarabine and busulfan with
ATG (high dose: 20 (25%); low dose: 50 (62%)) or of low dose
irradiation-based RIC (N11, 13%). With 26 (9–68) months
follow-up, 67 pts (83%) experienced at least one infectious episode
beyond the ﬁrst six months after allo-SCT developing at a median
of 8 (6–34) months. 221 infectious episodes were observed, of
which 123 (56%) required hospitalization and systemic anti-micro-
bial therapy. 94 episodes (43%) could be documented (bacterial,
n28; viral, n56; fungal, n10). Documented infections were:
gram negative bacteria (16%), other bacteria (14%), CMV positive
antigenemia (17%), HSV (25%), VZV (15%), other viruses (3%),
aspergillus (4%), candida species (6%). 81% pts (n54) with an
infection were under systemic immunosuppressive therapy for
chronic GVHD. Moreover, 24 pts (30%) experienced 1 episode
of documented infections (median, 2 episodes; range, 1–12). In a
univariate analysis performed in the pts with documented infec-
tion, age 
50 (P0.06), the use of PBSCs as stem cell source
(P0.03) and a history of DLI (P0.002), exerted a protective
effect against infection occurrence. In a multivariate analysis, DLI
was signiﬁcantly associated with a decreased risk of long term
infections (P0.002; RR0.23; 95% CI, 0.1–0.6), indirectly high-
lighting the protective effect of donor origin immunity after allo-
SCT. In this series of pts surviving at least 6 months after RIC
allo-SCT, the overall long term transplant-related mortality was
14% (n11), of whom 6 deaths were attributed to infections (3
bacterial septicemia, 2 aspergillosis, 1 pneumocystosis), giving a
cumulative incidence of long term-infectious related mortality of
7% (95% CI, 1.4–12.6%). Obviously, prospective efforts to de-
velop optimal antimicrobial preventive strategies after RIC allo-
SCT are still needed. However, the results from this analysis
compare favorably with data from the standard myeloablative allo-
SCT setting.
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DRAMATIC CHANGE IN TREATMENT RELATED MORTALITY (TRM) FOR
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) DURING RECENT
YEARS. A ONE CENTRE ANALYSIS
Heilmann, C.; Laursen, H.B.; Muller, K.; Haastrup, E.; Jacobsen, N.
BMT Unit, Rigshospitalet, University Hospital, Copenhagen, Denmark.
Background: During recent years it has been the impression in
many centres that TRM following allogeneic stem cell transplants
has declined signiﬁcantly. This impression has been strong in our
centre as well. The aim of the present study was to analyze the
magnitude of this presumed reduction in procedure related risks
and to examine possible causes. Method: We analyzed a recent
time period of ten years from Jan. 1994 to Jan. 2003. Non my-
eloablative transplants were excluded from the study. During this
period 224 and 219 standard allotransplants were performed dur-
ing the ﬁrst and the second 5-year time periods respectively. All
transplants were performed at the same centre (Copenhagen, Den-
mark), whose organization has essentially remained the same for
the whole time period. Results: TRM differed signiﬁcantly
(p
0.0001) between the two time periods. The one-year Kaplan-
Meier based TRM declined from 33.5% to 13.9%. On the basis of
univariate analysis no signiﬁcant differences was found between the
compositions of the main diagnosis (AML, ALL, MDS, CML,
non-malignant). Likewise, when the pre-transplant stages of acute
leukaemia and CML were compared between the two periods non
differences were recorded, except that slightly less very high risk
ALL patients were transplanted during the last period. No differ-
ence in age distribution was found. In contrast, a tendency for a
more restrictive donor selection policy could be recorded. Hence,
the composition of donor types (HLA-id Sib vs. other fam. donors
vs. UD; p0.007), donor gender (less female to men; p0.018) and
the use of class I high-resolution donor typing for UD (p0.0001)
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